We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$440M
1-Year Est. Return
109.12%
This Fund
S&P 500
This Quarter
Est. Return
-19.24%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$384M
AUM Growth
-$13.9M
(-3.5%)
Cap. Flow
+$77.9M
Cap. Flow
% of AUM
20.3%
Top 10 Holdings %
Top 10 Hldgs %
46.53%
Holding
98
New
11
Increased
36
Reduced
12
Closed
4
Top Buys
| 1 |
State Street SPDR S&P Biotech ETF
XBI
|
+$24.9M |
| 2 |
iShares Biotechnology ETF
IBB
|
+$8.02M |
| 3 |
Fate Therapeutics
FATE
|
+$4.99M |
| 4 |
Edgewise Therapeutics
EWTX
|
+$4.59M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$4.37M |
Top Sells
| 1 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$11.1M |
| 2 |
OTIC
Otonomy, Inc.
OTIC
|
+$1.49M |
| 3 |
HOOK
HOOKIPA Pharma
HOOK
|
+$747K |
| 4 |
ProQR Therapeutics
PRQR
|
+$685K |
| 5 |
Xenon Pharmaceuticals
XENE
|
+$674K |
Sector Composition
| 1 | Healthcare | 86.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Stereotaxis
STXS
$161M
| $51M | 13.3% |
13,680,554
| – | – |
|
|
2
State Street SPDR S&P Biotech ETF
XBI
$10.6B
| $24.2M | 6.31% |
+269,500
| New | +$24.9M |
|
|
3
Fate Therapeutics
FATE
$349M
| $19.4M | 5.06% |
500,930
+128,770
| +35% | +$4.99M |
|
|
BPMC
4
DELISTED
Blueprint Medicines
BPMC
| $15.7M | 4.1% |
246,280
+39,369
| +19% | +$2.83M |
|
5
Adicet Bio
ACET
$81.1M
| $14.3M | 3.73% |
44,742
-1,081
| -2% | -$249K |
|
|
6
iShares Biotechnology ETF
IBB
$9.24B
| $13.4M | 3.48% |
102,500
+61,600
| +151% | +$8.02M |
|
|
7
Xenon Pharmaceuticals
XENE
$6.55B
| $11.6M | 3.03% |
380,163
-22,504
| -6% | -$674K |
|
|
KRTX
8
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $10.4M | 2.71% |
82,053
+9,630
| +13% | +$1.08M |
|
9
DexCom
DXCM
$28.1B
| $9.28M | 2.42% |
72,552
| – | – |
|
|
BHVN
10
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $9.2M | 2.4% |
77,600
+19,500
| +34% | +$2.43M |
|
11
Neurocrine Biosciences
NBIX
$17.3B
| $7.84M | 2.04% |
83,655
| – | – |
|
12
Cytokinetics
CYTK
$11.2B
| $7.79M | 2.03% |
211,495
+77,401
| +58% | +$2.75M |
|
13
Nurix Therapeutics
NRIX
$2.48B
| $7.61M | 1.98% |
543,344
+237,024
| +77% | +$4.21M |
|
|
MORF
14
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $7.29M | 1.9% |
181,467
| – | – |
|
|
CSII
15
DELISTED
Cardiovascular Systems, Inc.
CSII
| $6.49M | 1.69% |
286,988
| – | – |
|
16
Syndax Pharmaceuticals
SNDX
$2.08B
| $6.46M | 1.68% |
371,987
+75,452
| +25% | +$1.27M |
|
|
MRUS
17
DELISTED
Merus
MRUS
| $6.21M | 1.62% |
234,989
+8,900
| +4% | +$239K |
|
|
SAGE
18
DELISTED
Sage Therapeutics
SAGE
| $5.97M | 1.56% |
180,306
| – | – |
|
19
Revolution Medicines
RVMD
$39.2B
| $5.92M | 1.54% |
232,101
+19,870
| +9% | +$432K |
|
20
IDEAYA Biosciences
IDYA
$3.54B
| $5.48M | 1.43% |
490,061
+30,000
| +7% | +$442K |
|
|
CBAY
21
DELISTED
Cymabay Therapeutics
CBAY
| $5.26M | 1.37% |
1,692,569
-95,000
| -5% | -$299K |
|
|
ISEE
22
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $5.02M | 1.31% |
298,476
+22,500
| +8% | +$333K |
|
|
NTUS
23
DELISTED
Natus Medical Inc
NTUS
| $5.01M | 1.31% |
190,635
| – | – |
|
|
APLS
24
DELISTED
Apellis Pharmaceuticals
APLS
| $4.77M | 1.24% |
+93,935
| New | +$4.15M |
|
25
AtriCure
ATRC
$1.75B
| $4.73M | 1.23% |
72,029
| – | – |
|
Similar funds
FGWP
STCG
SCP
CAAM
AWM
HCM
CPW
DWML